ArticleCureus2024
Quality of Life, Depression, and Psychological Distress Among Patients With Rheumatoid Arthritis Treated With Biologics.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of Biologic Drugs on Comorbidity Outcomes in Rheumatoid Arthritis: A Systematic Review.Journal of clinical medicine · 2025Review
- A Cross-Sectional Study of Quality of Life, Treatment Adherence, and Health-Seeking Behavior in Turkish Patients with Rheumatoid Arthritis: Gender and Education as Key Predictors.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of biologics has improved the management of rheumatoid arthritis (RA), enhancing disease control and quality of life for patients. However, despite these advancements, some individuals still experience distress and depression due to the effects of treatment and concerns about the outcomes of biologic therapy. This study aimed to evaluate the current quality of life, level of distress, and depression among RA patients treated with biologics, which could serve as a basis for intervention. The Quality of Life in Rheumatoid Arthritis Instrument II (QoL-RAII), Kessler Psychological Distress Scale (KPDS), and Beck Depression Inventory (BDI) were used to gather the necessary data. These standardized questionnaires were randomly administered to 100 RA patients undergoing biologic treatment. The data were then tabulated and analyzed using the mean and Pearson r correlation. The study's results revealed a low average quality of life and a very high level of psychological distress among the respondents. Additionally, there was an extreme level of depression observed in RA patients. Furthermore, a significant correlation was found between quality of life and the level of psychological distress among the patients. The findings concluded that RA patients have poor quality of life, experience very high levels of psychological distress, and suffer from extreme depression. The study underscored the urgent need for mental health professionals to provide immediate intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.